IVDs May Lose IDE Exemption Under BIMO Reengineering Reg Changes
This article was originally published in The Gray Sheet
Sponsors of in vitro diagnostic device clinical trials would be required to obtain investigational device exemptions from FDA under a regulation change currently being considered by the agency's bioresearch monitoring (BIMO) reengineering team.
You may also be interested in...
The bioresearch monitoring (BIMO) reengineering team within FDA's Center for Devices and Radiological Health is considering the use of pre-announced inspections of sponsors of medical device clinical investigations.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.